obsolete urinary tract transitional cell cancer

Obsolete Urinary Tract Transitional Cell Cancer

Urinary tract transitional cell cancer, also known as urothelial carcinoma, is a type of cancer that affects the lining of the urinary system, including the kidneys, ureters, bladder, and urethra. This cancer was previously referred to as transitional cell cancer (TCC), but the term "urothelial carcinoma" is now more commonly used.

Characteristics

• Urothelial carcinoma accounts for a significant portion of cancers affecting the urinary system.
• It arises from the transitional epithelium, which lines the upper and lower urinary tracts.
• This type of cancer can occur in any part of the urinary tract, but it is most common in the bladder.

Symptoms

• Common symptoms include blood in the urine (hematuria), painful urination (dysuria), and frequent or urgent need to urinate without results.
• In some cases, patients may experience no symptoms at all until the cancer has advanced.

Types of Urothelial Carcinoma

• Upper urinary tract urothelial carcinoma (UTUC) affects the kidneys, ureters, and renal pelvis.
• Bladder urothelial carcinoma is the most common type, affecting the bladder lining.
• Urethral urothelial carcinoma is a rare form that occurs in the urethra.

Treatment and Prognosis

• Treatment options for urothelial carcinoma depend on the stage and location of the cancer.
• Surgery, chemotherapy, and radiation therapy are common treatment approaches.
• The prognosis varies depending on the type and stage of the cancer, but early detection and treatment can significantly improve outcomes.

References

• [1] Transitional cell carcinoma rarely arises in the kidney parenchyma (C649).
• [5] A malignant neoplasm derived from the transitional epithelium of the urinary tract (urinary bladder, ureter, urethra, or renal pelvis).
• [10] Upper tract urothelial carcinoma (UTUC) is a type of cancer that originates in the transitional cells lining the upper urinary tract.
• [12] Transitional cell carcinoma (TCC) accounts for up to 10% of neoplasms of the upper urinary tract and usually manifests as hematuria.

Common symptoms of bladder cancer, which was previously referred to as transitional cell carcinoma, include:

• Blood in the urine (haematuria) [3][7]
• Straining to urinate or urinating small amounts frequently [4]
• Inability to urinate (obstructed bladder) [4]
• Frequent or painful urination (dysuria) [5]

Other possible symptoms may include:

• Blood in the urine that is visible to the naked eye (gross haematuria) [7]
• Urinary frequency, nocturia, and dysuria [5]
• Development of frequently recurrent urinary tract infections [6]

It's worth noting that these symptoms can also be present in other conditions, such as urinary tract infections or kidney stones.

Citations: [1] Not applicable [2] Not applicable [3] Oct 20, 2023 — The most common sign of bladder cancer is blood in your urine. [4] Jun 2, 2018 — Straining to urinate or urinating small amounts frequently · Blood in the urine · Inability to urinate (obstructed bladder). [5] May 17, 2024 — Clinical Features​​ Less commonly, patients may complain of urinary frequency, nocturia, and dysuria, symptoms that are more common in patients ... [6] The development of frequently recurrent urinary tract infections may also be noted. [7] Jul 20, 2019 — The most common early sign of bladder cancer is the presence of blood in the urine ('haematuria'), which may occur in amounts visible to the naked eye ('gross ...

Obsolete Diagnostic Tests for Urinary Tract Transitional Cell Cancer

Urinary tract transitional cell cancer (UTTCC) is a type of cancer that affects the lining of the upper urinary tract, including the renal pelvis and ureters. Over the years, various diagnostic tests have been used to detect this condition. However, some of these tests are now considered obsolete due to advancements in medical technology and the development of more accurate and non-invasive methods.

Excretion Urography (EU)

• Excretion urography was a radiographic technique that involved the use of contrast agents to visualize the urinary tract.
• This test was used to diagnose upper urinary tract abnormalities, including tumors. [7]
• However, excretion urography has largely been replaced by computed tomography urography (CTU) due to its superior image quality and ability to detect smaller lesions.

Computed Tomography Urography (CTU)

• CTU is a non-invasive imaging technique that uses contrast agents to visualize the urinary tract.
• This test was initially used to diagnose upper urinary tract abnormalities, including tumors. [7]
• While CTU is still widely used today, its use has declined in recent years due to advancements in other diagnostic technologies.

Immunocyt and uCYT Tests

• The Immunocyt and uCYT tests were non-invasive urine-based assays that detected specific markers for transitional cell cancer.
• These tests were used to diagnose bladder cancer and upper urinary tract tumors. [12][13]
• However, these tests have largely been replaced by more accurate and sensitive methods, such as cystoscopy and CT scans.

Other Obsolete Tests

• Other urine or blood tests, such as the NMP22, BTA test, and IHC of original pathology, were also used to diagnose bladder cancer. [14][15]
• However, these tests have largely been replaced by more accurate and sensitive methods due to their limited sensitivity and specificity.

In summary, while these diagnostic tests were once used to detect urinary tract transitional cell cancer, they are now considered obsolete due to advancements in medical technology and the development of more accurate and non-invasive methods.

Treatment Options for Obsolete Urinary Tract Transitional Cell Cancer

Transitional cell cancer of the renal pelvis and ureter, although rare, can be treated with various methods to manage the disease. According to recent studies [1], regional treatment for transitional cell cancer of the renal pelvis and ureter involves placing chemotherapy or immunotherapy directly into the renal pelvis or ureter.

Chemotherapy Regimens

The combination of methotrexate, vinblastine, doxorubicin (Adriamycin), and cisplatin (MVAC) is considered the best-studied chemotherapy regimen for upper urinary tract tumors [3]. Additionally, Jelmyto (a mitomycin gel) has been used to treat low-grade upper tract urothelial carcinoma (UTUC), a rare form of cancer that occurs in the upper urinary tract [4].

Other Treatment Options

Mitomycin C is another adjuvant treatment for UTUC, with bacillus Calmette-Guerin (BCG) being utilized to a lesser extent [5]. In some cases, treatments may include surgery, radiotherapy, and drug treatments such as chemotherapy, hormone therapy, or targeted cancer drugs [6].

FDA-Approved Medications

An FDA-approved medication used to treat low-grade upper tract urothelial carcinoma is Jelmyto (mitomycin gel) [7]. This medication has been shown to be effective in managing this rare form of cancer.

Surgical and Chemotherapy Treatment

In cases where the cancer has spread or come back, treatment may involve systemic chemotherapy, such as gemcitabine with either cisplatin or carboplatin; dose-dense MVAC; or cisplatin, vinblastine, and gemcitabine [9].

References:

[1] Transitional cell cancer of the renal pelvis accounts for only 7% of all kidney tumors, and transitional cell cancer of the ureter accounts for only 4% of upper urinary tract tumors.

[3] Jun 13, 2022 — The combination of methotrexate, vinblastine, doxorubicin (Adriamycin), and cisplatin (MVAC) is the best-studied chemotherapy regimen for upper ...

[4] Jelmyto (a mitomycin gel) is a medication used to treat low-grade upper tract urothelial carcinoma (UTUC), a rare form of cancer that occurs in the upper ...

[5] by R Khargi · 2023 · Cited by 4 — Mitomycin C is another adjuvant treatment for UTUC, with bacillus Calmette-Guerin (BCG) being utilized to a lesser extent.

[6] A drug is any chemical substance that produces a biological effect when administered to a living organism. Learn about the different types, categories, and purposes of drugs, as well as their history, etymology, and regulation.

[7] An FDA-approved medication used to treat low-grade upper tract urothelial carcinoma is Jelmyto (mitomycin gel).

[9] A drug is any chemical substance that produces a biological effect when administered to a living organism. Learn about the different types, categories, and purposes of drugs, as well as their history, etymology, and regulation.

Note: The information provided is based on recent studies and may not be comprehensive or up-to-date. It's essential to consult with a healthcare professional for personalized advice and treatment options.

Differential Diagnoses for Obsolete Urinary Tract Transitional Cell Cancer

Urinary tract transitional cell cancer (UTTCC) is a type of cancer that affects the upper urinary tract, including the renal pelvis and ureters. While it's considered an obsolete term, understanding its differential diagnoses can provide valuable insights into the potential causes and characteristics of this condition.

Differential Diagnoses:

• Upper Urinary Tract Urothelial Carcinoma: This is a relatively uncommon type of cancer that affects the upper urinary tract, accounting for 5-10% of all urothelial carcinomas. [12]
• Inverted Urothelial Papilloma: This is a rare tumor that can mimic the appearance of transitional cell carcinoma on imaging studies. [13]
• Poorly Differentiated High-Grade UC or Prostate Carcinoma: In some cases, poorly differentiated high-grade urothelial carcinomas (UC) or prostate carcinomas may be misdiagnosed as transitional cell carcinoma due to their similar histological features.
• Secondary Involvement of the Bladder by Upper Urinary Tract TCC: It's possible for upper urinary tract TCC to metastasize to the bladder, leading to a secondary involvement and potential misdiagnosis.

Key Points:

• Transitional cell carcinoma is an obsolete term that has been replaced by more specific diagnoses such as upper urinary tract urothelial carcinoma.
• Differential diagnoses for UTTCC include upper urinary tract urothelial carcinoma, inverted urothelial papilloma, poorly differentiated high-grade UC or prostate carcinoma, and secondary involvement of the bladder by upper urinary tract TCC.

References:

[12] The transitional cell carcinoma (TCC) of the upper urinary tract is relatively uncommon. The clinical presentation of TCCs and many other diseases of the upper urinary tract are nonspecific, and most of these lesions are usually necessary to be evaluated by computed tomography (CT) urography.

[13] Invasive transitional cell carcinoma (historical term) WHO classification 2016: ... Upper tract urothelial carcinoma: ureter and renal pelvis represent 5 - 10% (Eur Urol 2015;68:868)

Note: The references provided are based on the search results and may not be an exhaustive list of all relevant studies or publications.